SUSTOL — known as the generic drug granisetron — covers both the acute and delayed phases of CINV, preventing nausea for up to five days.
The FDA approved the injection based on results from two clinical trials including more than 2,000 patients that showed the safety and efficacy of the product.
Heron Therapeutics, based in Redwood City, Calif., expects to launch SUSTOL in the fourth quarter of 2016.
More articles on the drug market:
AstraZeneca cancer drug disappoints in lung cancer study
How this startup is lowering prescription drug costs
Merck’s blockbuster drug Keytruda approved to treat head and neck cancer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
